Previous studies of first-generation EGFR-TKI erlotinib and bevacizumab combination have demonstrated superior treatment efficacy compared to erlotinib monotherapy for advanced EGFR-mutant NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.